In Alzheimer’s disease (AD), the accumulation of cerebral amyloid-beta (Aβ) plaque pathology is assumed to initiate a cascade of pathological processes, including the expansion of hyperphosphorylated tau pathology from the temporal lobe to the cortex, thereby driving neurodegeneration and cognitive decline1,2. This evidence concerns the gene MAPT and Alzheimer disease.